Jubilant Pharmova share price has zoomed 6% and is presently trading at Rs 816.0.
Meanwhile, the BSE HEALTHCARE index is at 40,615.3 (up 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are ASTER DM HEALTHCARE (up 4.6%) and SYNGENE INTERNATIONAL (up 2.4%).
Pfizer (down 1.1%) and J.B.Chemicals (down 1.0%) are among the top losers today.
Over the last one year, Jubilant Pharmova has moved up from Rs 377.5 to Rs 816.0, registering a gain of Rs 438.6 (up 116.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,736.5 to 40,615.3, registering a gain of 46.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 116.2%), SUVEN PHARMACEUTICALS (up 100.9%) and Cadila Healthcare (up 99.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 82,016.6 (up 0.3%).
The top gainers among the BSE Sensex today are Maruti Suzuki (up 2.7%) and MUNDRA PORT & SEZ (up 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 25,044.4 (up 0.4%). Maruti Suzuki and Coal India are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,527.7 to 82,016.6, registering a gain of 15,488.9 points (up 23.3%).
Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.
For the year ended March 2023, Jubilant Pharmova reported 115.7% decrease in net profit to Rs -649 million compared to net profit of Rs 4,130 million during FY22. Revenue of the company grew 2.5% to Rs 62,817 million during FY23.
The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 24.9.
Equitymaster requests your view! Post a comment on "Jubilant Pharmova Gains 6%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!